Floatz logo

Fluciclovine

Metastatic Prostate Neuroendocrine Carcinoma

Brigham and Women's HospitalradiopharmaceuticalPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

32 Active assets in the Metastatic Prostate Neuroendocrine Carcinoma cohort.

Asset / SponsorPhaseRating
Carboplatin
Phanes Therapeutics
Phase 2BB
Oxodotreotide
Novartis Pharmaceuticals
Phase 2B
Tarlatamab
Inkeun Park
Phase 2B
Alisertib
Weill Medical College of Cornell University
Phase 2B
Sacituzumab Tirumotecan
Virginia Commonwealth University
Phase 2CCC

View all 35 →

Same molecule, other indications

Fluciclovine is also rated in:

metastatic prostate carcinomaDormant
BBB
Indicative ·
73 / 100
View asset →
prostate cancerDormant
BB
Indicative ·
71 / 100
View asset →
prostate carcinomaDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →